David Seymour Ettinger MD
Professor of Oncology, Professor of Gynecology and Obstetrics, Professor of Medicine, Professor of Otolaryngology-Head and Neck Surgery, Professor of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine
Join to View Full Profile
10755 Falls RdLutherville, MD 21093
Phone+1 410-583-2970
Dr. Ettinger is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Johns Hopkins UniversityResidency, Internal Medicine, 1973 - 1975
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1968 - 1971
Albany Medical CenterInternship, Transitional Year, 1967 - 1968
University of Louisville School of MedicineClass of 1967
Certifications & Licensure
MD State Medical License 1974 - 2024
DC State Medical License 2013 - 2020
MN State Medical License 1968 - 1987
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2014, 2016-2017
Clinical Trials
- Chemotherapy Plus Radiation Therapy With or Without Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer Start of enrollment: 1994 Mar 01
- Octreotide With or Without Prednisone in Treating Patients With Metastatic or Recurrent Thymoma Start of enrollment: 1998 Oct 13
- Preoperative Thalidomide With Radiation Therapy For Patients With Low-Grade Primary Soft Tissue Sarcoma or Thalidomide With Radiation Therapy and Chemotherapy For Patients With High-Grade or Intermediate-Grade Primary Soft Tissue Sarcoma of the Arm, Leg, or Body Wall Start of enrollment: 2004 Jun 17
Publications & Presentations
PubMed
- Distinct size and spatial distribution patterns of ALK-inhibitor-naïve versus ALK-inhibitor exposed ALK-positive NSCLC brain metastases.Tia Cheunkarndee, Zsombor Ritter, Max Saint-Germain, Paola Ghanem, Kristen A Marrone
Journal of Neuro-Oncology. 2025-11-01 - 398 citationsNon-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in OncologyGregory J Riely, Douglas E Wood, David S Ettinger, Dara L Aisner, Wallace Akerley
Journal of the National Comprehensive Cancer Network. 2024-05-01 - 3 citationsImpact of Tumor-intrinsic Molecular Features on Survival and Acquired Tyrosine Kinase Inhibitor Resistance in ALK-positive NSCLC.Mari Nakazawa, Guilherme Harada, Paola Ghanem, Adrian Bubie, Lesli A Kiedrowski
Cancer Research Communications. 2024-03-14
Press Mentions
PD-L1 Inhibitor Avelumab May Improve Survival in Metastatic Urothelial CarcinomaOctober 7th, 2015- Dr David Ettinger Discusses the Road Ahead for Immunotherapy in NSCLCOctober 6th, 2015
Honoring the Women of the Kimmel Cancer CenterJanuary 1st, 2001
Grant Support
- Eastern Cooperative Oncology GroupNational Cancer Institute1985–1992
Professional Memberships
- Member
External Links
- Johns Hopkins Physicianshttp://www.hopkinsmedicine.org/david-ettinger
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
